ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-CNTN4 Monoclonal Antibody GENA-104A16

Also written as “BI-1607” and “GENA-104A16”.

Its studies are mostly in Uveal Melanoma · Breast Neoplasms, led by 2 companies.

Drug pageAnti-CNTN4 Monoclonal Antibody GENA-104A16: every studyAll 3 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Sep 22, 20223 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioInvent International ABits history only21 open or runningphase 2since Sep 22, 2022Sep 22, 2022none ahead
Genomeits history only10 open or runningphase 1since Jan 15, 2024Jan 15, 2024none ahead

Also a collaborator on its studies: Merck.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of every company. Pick one to see its own:

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 22, 2022First study: phase 2 study in HER2-positive Breast CancerNew to BioInvent International ABBioInvent International AB · NCT05555251 · 18 enrolled · Germany, Spain, United Kingdom
  2. Jan 15, 2024Genome’s first study: phase 1 study in Advanced Solid TumorsNew to GenomeGenome · NCT06235541 · South Korea
  3. Dec 16, 2024Phase 2 study in MelanomaBioInvent International AB · NCT06784648 · 35 enrolled · Germany, Spain, United Kingdom

TargetBeta

CNTN4 →read by rule
“An affinity-matured humanized monoclonal antibody directed against the inhibitory immune checkpoint protein contactin 4 (contactin-4; CNTN4), ”NCIt, by rule

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06784648Melanoma · Germany, Spain, United Kingdom2Active, not recruitingBioInvent International ABSep 9, 202635
NCT06235541Advanced Solid Tumors · South Korea1WithdrawnGenomeSep 20260
NCT05555251HER2-positive Breast Cancer · Germany, Spain, United Kingdom2TerminatedBioInvent International ABFeb 7, 202418

How it is read

Names in the registry

  • “BI-1607”, 3 entries
  • “GENA-104A16”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.